Emideltide
Delta sleep inducing peptide, DSIP
A nine amino acid peptide that makes the brain release its own opioids, sold for sleep.
Emideltide is the one peptide of the seven that an FDA advisory committee refused in July 2026, and the only one with a real clinical literature going back to 1981. That literature contradicts itself: four studies by one author found better sleep, two comparable controlled studies by other groups found nothing. Every one of them used a drip into a vein, not the injection under the skin that clinics sell.
Where it stands, jurisdiction by jurisdiction
United States
Unregulated, unregulated, sold anywayDecided on: Precaution, Contested
Not a lawful dietary ingredient and not on the 503A list. Nominated as a 1 milligram per milliliter injection under the skin for chronic insomnia, narcolepsy and opioid withdrawal, and sold through neurology clinics, concierge medicine, medical spas and online retailers. FDA found the insomnia trials inconclusive, narcolepsy resting on a single case report, and opioid withdrawal on an open label study of 107 people with no control group in which three had serious adverse events including low blood pressure. Because emideltide triggers release of the body's own opioids, FDA raised addiction and found nobody had studied it. The advisory committee voted against adding it, 6 for and 7 against with one abstention, on 24 July 2026.
Regulatory positions change, sometimes quickly. Check the date on a source before relying on it.